Editorial Commentary
Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 study
Translational Andrology and Urology
2026;
15
(1)
:1
.
(31 January 2026)
Pembrolizumab in metastatic hormone-sensitive prostate cancer: lessons from the negative KEYNOTE-991 trial
Translational Andrology and Urology
2026;
15
(1)
:2
.
(31 January 2026)
Insights from PSMAfore: impact on health-related quality of life
Translational Andrology and Urology
2026;
15
(1)
:3
.
(31 January 2026)
Is it time to say “shorter, safer, and smarter”?—interpreting early toxicity data from the PACE-C non-inferiority trial
Translational Andrology and Urology
2026;
15
(1)
:4
.
(31 January 2026)
Rethinking combination strategies in metastatic castration-resistant prostate cancer (mCRPC)—lessons from KEYNOTE-641
Translational Andrology and Urology
2026;
15
(1)
:5
.
(31 January 2026)
The evolving role of adjuvant immune checkpoint inhibitors in urothelial carcinoma
Translational Andrology and Urology
2026;
15
(1)
:6
.
(31 January 2026)
Clinical implication of immune check point inhibitors in advanced prostate cancer: insight from the KEYNOTE-991 trial
Translational Andrology and Urology
2026;
15
(1)
:7
.
(31 January 2026)
First-line enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma—commentary on patient-reported outcomes in EV-302
Translational Andrology and Urology
2026;
15
(1)
:8
.
(31 January 2026)
Original Article
Clinical characteristics and outcomes of relapse in unilateral Wilms tumor: a single-institution report from 2010 to 2022
Translational Andrology and Urology
2026;
15
(1)
:9
.
(31 January 2026)
Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2025 at the 112th Annual Meeting of the Japanese Urological Association
Translational Andrology and Urology
2026;
15
(1)
:10
.
(31 January 2026)
METS-VF outperforms traditional adiposity indices in predicting overactive bladder risk: a NHANES-based cross-sectional study
Translational Andrology and Urology
2026;
15
(1)
:11
.
(31 January 2026)
Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in relation to erectile dysfunction: a cross-sectional study
Translational Andrology and Urology
2026;
15
(1)
:12
.
(31 January 2026)
Palmitoylation-related gene expression and its prognostic value in prostate cancer: insights into immune infiltration and therapeutic potential
Translational Andrology and Urology
2026;
15
(1)
:13
.
(31 January 2026)
Positive and non-linear association of sagittal abdominal diameter-to-height ratio with stress urinary incontinence in US women: evidence from NHANES 2011–2016
Translational Andrology and Urology
2026;
15
(1)
:14
.
(31 January 2026)
Low expression and significance of AOC1 in prostate adenocarcinoma
Translational Andrology and Urology
2026;
15
(1)
:15
.
(31 January 2026)
Tubularized augmented peritoneal cap (TAPCap) with intact fish skin xenograft for primary gender-affirming vaginoplasty: early experience and surgical results
Translational Andrology and Urology
2026;
15
(1)
:16
.
(31 January 2026)
Ex vivo feasibility study of vasovasostomy utilizing a novel microsurgery platform versus manual microsurgery
Translational Andrology and Urology
2026;
15
(1)
:17
.
(31 January 2026)
Construction and verification of a prognostic model of neutrophil-related genes in clear cell renal cell carcinoma
Translational Andrology and Urology
2026;
15
(1)
:18
.
(31 January 2026)
Overview of tumor-resident intratumoral microbiota in human bladder cancer
Translational Andrology and Urology
2026;
15
(1)
:19
.
(31 January 2026)
Modified three-arm port configuration for single-position, single-docking robotic nephroureterectomy: perioperative and oncological outcomes
Translational Andrology and Urology
2026;
15
(1)
:20
.
(31 January 2026)
Viable sperm DNA fragmentation index (SDF) provides better diagnostic accuracy than total SDF in male infertility: a cross-sectional study
Translational Andrology and Urology
2026;
15
(1)
:21
.
(31 January 2026)
Color Doppler ultrasound results of erectile dysfunction patients after an intracavernosal injection of prostaglandin E1: an analysis of 9,109 cases
Translational Andrology and Urology
2026;
15
(1)
:22
.
(31 January 2026)
Application of serum miRNA panel in bladder cancer detection
Translational Andrology and Urology
2026;
15
(1)
:23
.
(31 January 2026)
Upregulation of NME4 is associated with progression and poor prognosis in clear cell renal cell carcinoma
Translational Andrology and Urology
2026;
15
(1)
:24
.
(31 January 2026)
Rete testis thickness is a novel predictor for Johnsen score and sperm retrieval outcomes in azoospermia
Translational Andrology and Urology
2026;
15
(1)
:25
.
(31 January 2026)
Shorter interval between consecutive testicular sperm aspirations and clinical pregnancy after intracytoplasmic sperm injection in obstructive azoospermia: a retrospective cohort study
Translational Andrology and Urology
2026;
15
(1)
:26
.
(31 January 2026)
Case Series
Mixed epithelial and stromal tumor of the kidney: a case series of clinical diversity in atypical presentations
Translational Andrology and Urology
2026;
15
(1)
:27
.
(31 January 2026)
Feasibility and short-term outcomes of the dorsal inlay skin flap for challenging distal penile urethral strictures—a novel case series
Translational Andrology and Urology
2026;
15
(1)
:28
.
(31 January 2026)
Review Article
Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions
Translational Andrology and Urology
2026;
15
(1)
:29
.
(31 January 2026)
Editorial
Preface to “Minimally Invasive Treatments for Urethral Stenosis”
Translational Andrology and Urology
2026;
15
(1)
:30
.
(31 January 2026)
Letter to the Editor
Clarification of methodology and findings from the NeuroSAFE PROOF randomised controlled trial
Translational Andrology and Urology
2026;
15
(1)
:31
.
(31 January 2026)
